A Single Ascending Dose Study for the Evaluation of the Effects of LY3039478 on the QT/Corrected QT Interval in Healthy Subjects and Pilot Relative Bioavailability

Trial Profile

A Single Ascending Dose Study for the Evaluation of the Effects of LY3039478 on the QT/Corrected QT Interval in Healthy Subjects and Pilot Relative Bioavailability

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Crenigacestat (Primary)
  • Indications Acute lymphoblastic leukaemia; Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 30 Oct 2017 Results from this and 2 otehr studies, presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
    • 25 Oct 2017 Outcomes of population PK/PD model developed using data from first human dose trial (NCT01695005,n=102) and single ascending dose and pilot relative bioavailability study (NCT02659865,n=34),presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017.
    • 11 Jul 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top